Genetic testing in clinical pediatric practice by Han Wook Yoo
Korean Journal of Pediatrics Vol. 53, No. 3, 2010
DOI : 10.3345/kjp.2010.53.3.273 Review article
- 273 -
1)jtj
Introduction
Recent progress in human genome research has accele-
rated the discovery of individual genes. This progress has
also augmented our understanding of how genes work to-
gether and how genetic defects lead to the development of
disease. Therefore, the possibility of analyzing individual
genes and detecting the specific defects that are responsi-
ble for human genetic disorders has now reached the point
where genetic testing is becoming an integral part of clini-
cal practice. This increase in genetic information has been
accompanied by a rapid evolution of diverse technologies
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for making accurate and efficient diagnoses. For instance,
a number of platforms have been developed for detecting
molecular defects, including sequencing technologies, multi-
plex ligation dependent probe amplification (MLPA), micro-
arrays, oligonucleotide ligation assays, and triplet expansion
assays. Methods for detecting structural chromosome ab-
normalities, such as fluorescent in situ hybridization (FISH)
and array comparative genomic hybridization (CGH) are
also available. Genetic testing is presently used to diagnose
rare monogenic genetic disorders or chromosomal disorders,
but will ultimately be extensively applied to assess the
susceptibility to common multifactorial disorders or predict
the response to a specific medication
1-3). Because clinical
practitioners are responsible for most day-to-day clinical
care, including the initial assessment of medical problems,
prevention, and long-term care, they will need to incorpo-
rate and effectively apply an exponentially increasing
amount of information with regard to genetic testing and
the clinical implications thereof. Notably, pediatricians are
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= Abstract =
Completion of the human genome project has allowed a deeper understanding of molecular pathophysiology and has
provided invaluable genomic information for the diagnosis of genetic disorders. Advent of new technologies has lead to
an explosion in genetic testing. However, this overwhelming stream of genetic information often misleads physicians and
patients into a misguided faith in the power of genetic testing. Moreover, genetic testing raises a number of ethical,
legal, and social issues. Diagnostic genetic tests can be divided into three primary but overlapping categories: cytogenetic
studies (including routine karyotyping, high-resolution karyotyping, and fluorescent in situ hybridization studies), bioche-
mical tests, and DNA-based diagnostic tests. DNA-based testing has grown rapidly over the past decade and includes pre-
and postnatal testing for the diagnosis of genetic diseases, testing for carriers of genetic diseases, genetic testing for
susceptibility to common non-genetic diseases, and screening for common genetic diseases in a particular population.
Theoretically, once a gene’s structure, function, and association with a disease are well established, the clinical application
of genetic testing should be feasible. However, for routine applications in a clinical setting, such tests must satisfy a num-
ber of criteria. These criteria include an acceptable degree of clinical and analytical validity, support of a quality assurance
program, possibility of modifying the course of the diagnosed disease with treatment, inclusion of pre-and postnatal ge-
netic counseling, and determination of whether the proposed test satisfies cost-benefit criteria and should replace or com-
plement traditional tests. In the near future, the application of genetic testing to common diseases is expected to expand
and will likely be extended to include individual pharmacogenetic assessments. (Korean J Pediatr 2010;53:273-285)
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the first to encounter patients with genetic disorders or
birth defects. This review will discuss the definition, classi-
fication, and evolving history of genetic testing and provide
comments with regard to the clinical validity, utility, and
limitations of such tests. The ethical, legal, and social im-
plications of genetic testing will also be addressed.
Definition of genetic testing
Genetic testing is defined as the analysis of human DNA,
RNA, chromosomes, proteins, and certain metabolites with
the aim of detecting heritable disease-related genotypes,
mutations, phenotypes, or karyotypes for clinical purposes
1). A growing number of cytogenetic, molecular cytogenetic,
biochemical, and DNA-based tests are being used to diag-
nose genetic disorders. Here, the focus of a vast majority
of the discussion will be on DNA-based genetic testing
with some consideration given to molecular cytogenetic
testing.
Classification of genetic testing
1. Classification of genetic testing based on the purpose
of the test
2)
1) Genetic testing for patients who have developed a
disease: confirmatory diagnostic tests. Analysis of a dis-
ease-causing gene mutation or chromosome structure is
carried out in patients with an established clinical diagnosis
in order to confirm the clinical diagnosis. Examples include
monogenic disorders (>1,500 diseases) and microdeletion
syndromes, of which more than 20 are currently known.
2) Genetic testing for detecting carrier status: screening
of an at-risk family member. When there is an affected
patient with an autosomal recessive, X-linked recessive
disorder, unbalanced chromosomal translocation, or chro-
mosome microdeletion/duplication syndrome in a family,
genetic testing is performed to determine whether exami-
nees are carriers and whether the offspring may be affected
by the same disorder.
3) Genetic testing to predict disorders. This includes
presymptomatic testing that is almost completely predictive
for the development of a genetic disorder caused by single
gene defect. This type of testing includes susceptibility
testing that evaluates the predisposition toward or risk of
acquiring a multifactorial disease. Examples include adult-
onset neurogenetic diseases, familial cancer syndromes, and
Alzheimer s disease. ’
(1) Presymptomatic genetic testing. Testing for a dis-
ease where effective therapies or preventive methods are
unavailable should not be offered in pediatric patients for
ethical/legal reasons.
(2) Disease-susceptibility genetic testing. It should be
established that analytical validity and clinical utility are at
acceptable levels. Typical applications include insulin-
dependent diabetes mellitus, obesity, hypertension, and
hyperlipidemia.
(3) Genetic testing for familial cancer syndromes. Such
testing should be approached cautiously, taking into ac-
count the possibility (or likelihood) that many diverse
tumor-related genes are involved. Examples include retino-
blastoma, osteosarcoma, breast cancer, and colon cancer.
4) Genetic testing for individual, differential drug res-
ponsiveness: pharmacogenetic testing. This includes the
diagnosis of sensitivity to drugs by genetic testing based on
polymorphisms in drug-metabolizing enzymes, receptors,
or transporters that affect pharmacokinetics or pharmaco-
dynamics (e.g., warfarin dosing and sensitivity to antie-
pileptic medications).
5) Prenatal genetic testing and diagnosis. Prenatal tests
includes cytogenetic, biochemical genetic, and DNA-based
tests using preimplantation diagnosis (PGD), chorionic villi
sampling (CVS), amniocentesis, and cordocentesis (cord
blood sampling), depending on the gestational age. An ex-
tremely cautious approach should be taken since these
tests raise numerous ethical, legal, and social issues.
6) Biochemical genetic testing: mass screening for
newborns. These tests seek to identify affected newborns
before the onset of symptoms in order to prevent detri-
mental consequences by appropriately treating or managing
patients. Diseases suitable for mass screening should fulfill
the following criteria: (i) the incidence should be relatively
high, (ii) clinical diagnosis should be problematic prior to
the onset of symptoms, (iii) effective screening tools with
a reasonable economic burden and analytical validity should
be available, and (iv) once diagnosed, measures should be
available to prevent or treat the disease.
2. Classification of genetic testing based on choice of
material to test
3) (Table 1)
1) DNA-based testing: two strategies direct and indirect —
analyses are available. Completion of the human genome —Genetic testing in clinical pediatric practice
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project has enabled the development of direct mutation
analysis of most genetic disorders caused by a single gene
defect. In cases where genetic homogeneity is predominant
in the disease, mutation analysis can be targeted to a spe-
cific mutation or region of the gene instead of requiring
sequencing of the entire gene. Indirect assessment using
linkage analysis is useful if the disease gene has not yet
been identified but has been mapped, or if the process of
identifying mutations is problematic (e.g., because of ex-
tensive genetic heterogeneity or an extremely large gene
size). However, this approach necessitates the presence of
informative genetic marker (s) located near a disease gene,
and the availability of specimens from additional family
members. The technologies developed for such DNA-based
genetic testing include polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP), DNA se-
quencing (including genomic and cDNA sequencing), micro-
arrays, allele-specific oligonucleotide (ASO) hybridization,
and MLPA.
2) Molecular cytogenetic testing. As new technologies
such as array CGH, spectral karyotyping, and subtelomeric
and multicolor FISH have developed, it has become clear
that a subset of dysmorphic patients with developmental
delay have microdeletions or structural rearrangements in
chromosomes. Molecular cytogenetic testing progressed
during the late 1980s with the introduction of FISH analy-
sis, and has since evolved into what might be called the
array CGH era. Recent advances in molecular cytogenetics
are rapidly increasing the resolution of such analyses,
providing insight into the dynamic nature of the human
genome structure.
3) Cytogenetic genetic testing. Conventional chromosome
analysis enables the detection of alterations in chromosome
number and structure. Current routine cytogenetic analysis
uses a banding technique to achieve a resolution of about
5 to 10 megabases of DNA. A metaphase chromosome
spread will usually show 350-500 bands, and high resolu-
tion banding is able to show 500-850 bands.
4) Biochemical genetic diagnosis. These tests are carried
out to screen or diagnose newborns affected by inborn
errors of metabolism. Individual inherited metabolic disor-
ders are rare, but in the aggregate, they have a major
impact at the population level. Since Archibald Garrod in-
troduced the concept of "inborn error of metabolism" or
"chemical individuality," more than 600 such diseases have
been identified that collectively affect approximately one
in 500 newborns. Many sophisticated laboratory tests are
available for the confirmatory diagnosis of each disease.
This diversity poses a challenge to the general pediatrician,
who must be knowledgeable about an array of biochemical
metabolite assays based on high-performance liquid chro-
matography (HPLC) and tandem mass spectrometry as
well as enzymatic assays.
3. Classification of genetic testing based on clinical
utility and validity
4)
1) Clinical genetic testing. Clinical tests are defined by
having specimens examined and results reported to the
provider or patient for the purpose of diagnosis, prevention,
or treatment of individual patients. Laboratories performing
research testing are not subject to site visit inspections or
regulations such as proficiency testing and registration.
There is a charge for clinical tests, and costs vary accor-
ding to the complexity of the test. Test results are reported
in writing.
2) Research genetic testing. Research tests are those
in which specimens are examined for the purpose of achie-
ving a better understanding of a condition or developing a
Table 1. Classification of Genetic Testing Based on Purpose and Choice of Material to Test
Specimen
Purpose DNA-based genetic testing Molecular
cytogenetic testing
Cytogenetic
testing
Biochemical
genetic testing
DNA profiling
Disease diagnosis
(confirmatory, prenatal,
presymptomatic)
Disease prediction
(susceptibility testing,
pharmacogenetic testing)
Paternity testing, individual
identification (forensic medicine)
Single gene Mendelian genetic
disorders, mitochondrial disorders,
familial cancer syndrome
Alzheimer’s disease, hypertension,
cancer, psychiatric disorder,
coronary artery disease,
prediction of drug response
Chromosome
microdeletion/
duplication
syndromes
Numerical &
structural
chromosome
abnormalities
Inborn errors
of metabolism
Maternal serum
biomarker screeningHW Yoo
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clinical test. Laboratories performing research testing are
not subject to regulations. The cost of research testing is
generally covered by the researcher. Test results are ge-
nerally not given to patients or their providers, but are
instead typically reported in peer-reviewed journals after
removing patient identification information.
3) Investigational genetic testing. Investigational tests
are tests that are perceived to have value, but that have
not yet been scientifically validated or generally accepted
by the medical community as accurate and useful. Test
results may or may not be shared, and it may be a long
time before results are made available.
A brief history of genetic testing
The first example of a genetic test was the analysis of
chromosome number and structure, first reported in 1959
by Jerome Lejeune, who diagnosed Down syndrome as tri-
somy of chromosome 21 after determining that the correct
human chromosome number was 2N=46 in 1956. In fact,
routine cytogenetic studies were made possible by the
advent of hypotonic treatment of dividing cells to spread
the chromosomes and by the development of cell culture
methods in the 1950s. In 1960, prenatal determination of
sex became possible. In 1961, a biochemical screening
method using a bacterial inhibition assay was invented to
detect phenylketonuria and was applied in a population-
based screen of newborns in Massachusetts in 1963. The
first successful prenatal chromosomal analysis was re-
ported in 1966, opening the door to prenatal genetic testing.
Subsequently, maternal serum biomarker screening was
initiated with a screen for -fetoprotein in 1972. In the α
following year, an association between HLA type and dis-
ease was used to predict disease susceptibility. The first
DNA-based genetic test for sickle cell anemia was suc-
cessfully applied in 1978. Two major factors that greatly
accelerated the expansion of DNA-based genetic testing
were the discovery and subsequent widespread availability
of a large variety of restriction enzymes in the late 1970s
and the development of polymerase chain reaction (PCR)
technology in the mid 1980s. Two advanced methods for
DNA sequencing were reported simultaneously in 1977,
for which Sanger and Gilbert shared the Nobel Prize in
chemistry in 1980. Since then, the Sanger dideoxy method
for DNA sequencing has remained the standard sequencing
technology, although major advances in automation and
other modification were made in the 1990s. During this
time, molecular cytogenetic testing technology has also
progressed. The FISH technique was introduced in the late
1980s. Multicolor FISH, spectral karyotyping, and CGH
technologies subsequently became available to identify
minute structural aberrations of chromosomes. Since the
turn of the century, there has been explosive development
of automation and high-throughput tools. Most recently,
the next generation of technology based upon massively
parallel DNA sequencing was invented
5-7).
Clinical utility and validity of genetic testing
1. Prerequisites for DNA-based genetic testing
1) For DNA-based testing of genetic disorders caused
by a single gene defect, the structure or locus of the res-
ponsible gene and the function of the gene product must
be known.
2) If the gene has not been cloned, an informative DNA
marker linked to the gene should be available to track the
segregation pattern of the marker in a family at risk.
3) Ideally, the defect of one gene leads to one genetic
disorder (i.e., limited locus heterogeneity).
4) Genetic epidemiology data pertaining to the particular
ethnicity of the examinee should be available and accessible.
5) Sufficient levels of analytical accuracy, clinical validity,
and utility should be guaranteed.
6) Pre- and post-test genetic counseling should be pro-
vided.
7) The right of examinees to choose whether to be in-
formed of test results should be respected and taken into
account
1-3, 8, 9).
2. Technologies used for DNA-based genetic testing
(Table 2)
This section describes methods used for mutation scan-
ning include denaturing HPLC, DGGE (denaturing gradient
gel electrophoresis), and two-dimensional gene scanning
(TDGS). To date, genetic testing as a tool for diagnosing
genetic disease has concentrated on identifying point mut-
ations (including base substitutions and small deletions/
insertions) by PCR and direct sequence analysis. However,
it is difficult to identify large deletions and duplications by
routine PCR gel-based assays, especially for genes with a
heterozygous status. For the detection of large deletionsGenetic testing in clinical pediatric practice
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or insertions, Southern blots or MLPA is needed. MLPA is
a PCR-based method that can detect gene dosage. Since its
introduction, it has been used to test a number of genes for
large deletions or duplication mutations. By using MLPA to
evaluate gene dosage, it is possible to detect large patho-
genic deletion/duplications. In addition to detecting gene
dosage, MLPA can be used to verify the methylation pat-
terns of target genes, determine aneuploidy in prenatal
diagnosis, and identify large deletions and duplications in
applications related to cancer genetics. This simple method
is advantageous because it requires only a small amount of
template DNA and based on flexible principles that allow
for multiple applications, including high-throughput appli-
cations. The disadvantages of MLPA include the possibility
of false positives caused by poor template DNA quality,
confounding of results due to SNPs being located within
probe sequences, and complications associated with quanti-
tative analysis
3, 10, 11).
3. Genetic testing in monogenic disorders (Table 3)
Clinical genetic tests are currently available for more
than 1,600 rare genetic disorders
4). Recently, there has
been a veritable explosion in the application of DNA-based
genetic testing for monogenic Mendelian disorders to con-
firm an existing diagnosis or for prenatal diagnostic pur-
poses. While genetic testing might merely complement
other tests, it is often more expensive because many of
such tests are not reimbursed by insurance. Moreover,
interpretations of test results may be problematic in some
cases. Therefore, pre- and post-test genetic counseling
should be provided to examinees. Physicians offering tests
are required to fully understand the clinical and analytical
validity as well as the pros and cons of genetic testing.
The following list provides some examples of monogenic
disorders where DNA-based genetic testing is justified
4,
11-13):
1) Inherited metabolic disorders: urea cycle defects,
Wilson disease, Gaucher disease, Tay-Sachs disease, gly-
cogen storage disease (GSD) type Ia, hemochromatosis,
fatty acid oxidation disorders, and cystic fibrosis
2) Skeletal dysplasia: achondroplasia and craniosynosto-
sis syndrome
3) Neuromuscular disorders: progressive muscular dys-
trophy (DMD/BMD) and spinal muscular atrophy
4) Triplet-repeat expansion disorders: spinocerebellar
ataxia, fragile-X syndrome, myotonic dystrophy, Kennedy
disease, and Huntington's disease
5) Neurogenetic disorders: Canavan disease, adrenoleu-
kodystrophy, and metachromatic leukodystrophy
6) Hematologic disorders: hemophilia, factor V Leiden,
and prothrombin
7) Familial cancer syndromes: retinoblastoma (Rb),
breast cancer, colon cancer, and ovarian cancer
8) Dysmorphic syndromes: Treacher-Collins syndrome,
Rett syndrome, Waadenburg syndrome, Holt-Oram synd-
rome, Marfan syndrome, and Smith-Lemli-Opitz syndrome
9) Mitochondrial disorders: MELAS (Mitochondrial myo-
pathy, encephalomyopathy, lactic acidosis, stroke-like
symptoms), MERRF (Myoclonic Epilepsy with Ragged Red
Fibers), LHON (Leber's hereditary optic neuropathy), and
Kearn-Sayers syndrome
10) Endocrine disorders: multiple endocrine neoplasia,
adrenal hypoplasia congenita, congenital lipoid adrenal hy-
perplasia, growth hormone (GH) deficiency, and GH resis-
Table 2. Technologies Utilized for DNA-Based Genetic Testing
Allele-specific PCR/ARMS
(amplification refractory mutation system)
Bead array
Invader chemistry
Mass spectrometry
Microarray technology
MLPA (multiplex ligation probe amplification)
Mutation scanning using dHPLC, SSCP, DGGE, TGGE, hete-
roduplex analysis, melting curve analysis
Oligonucleotide ligation assay (OLA)
PCR, bisulfite with methylation-specific primers
PCR, followed by capillary electrophoresis
PCR, followed by gel electrophoresis
(agarose, polyacrylamide, etc.)
PCR, GeneScan fragment size analysis
PCR, followed by heteroduplex analysis
PCR, real-time with intercalating dye (e.g. SYBR Green)
PCR, real-time with allele-specific probe
PCR, melting curve analysis with intercalating dye
(e.g. SYBR Green)
PCR, melting curve analysis with allele-specific probe
PCR, followed by RFLP assessment (restriction enzyme digestion)
PCR, followed by membrane transfer and probe hybridization
PCR, long distance
PCR, multiplex
PCR-based assay capable of differentiating methylated sites
PCR-based assay targeted at SNRPN gene expression
Pyrosequencing
Sequencing
Southern blot (without prior PCR amplification)
Southern blot using methylation sensitive restriction enzymesHW Yoo
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tance syndrome
11) Renal disorders: polycystic kidney disease and Alport
syndrome
12) Immune disorders: agammaglobulinemia and chronic
granulomatous disease (CGD)
4. DNA-based genetic testing for epigenetic disorders
(Table 4)
Epigenetics is a newly emerging field of human genetics.
Epigenetic change is characterized by the alteration of gene
expression without a permanent change in the genetic in-
formation. Several mechanisms to account for epigenetic
changes have been elucidated, including DNA methylation
at CpG dinucleotides in the promoter region of the gene,
histone modification by acetylation/deacetylation, and non-
coding microRNA interference at the transcription level.
Epigenetic changes have been shown to contribute to se-
veral genetic disorders through genomic imprinting. Geno-
mic imprinting is caused by differential expression of a
gene depending on whether it is inherited maternally or
paternally (otherwise known as the so-called parent-of- “
origin effect ). DNA-based genetic testing of genomic im ” -
printing associated with differential methylation is based on
bisulfite treatment of DNA, followed by amplification and
differential digestion with restriction enzymes. As shown
Table 3. Single Gene Disorders and Responsible Genes Where DNA-Based Genetic Testing Is Offered by the Medical Genetics Clinic
& Laboratory, Asan Medical Center Children’s Hospital (Continue)
Category OMIM Disease OMIM Gene Location
Cancer
disease
Cutaneous
disease
Dysmorphic
syndrome
#175200
#193300
#194070
#192500
+152427
#603830
#176670
#308300
#275210
#275210
#118450
#105830
#207410
#208085
#300419
#130650
#214800
#613013
#176450
#109400
#142900
#154700
#608967
#610380
#162200
#101000
#163950
#163950
#151100
#310600
#176270
#180849
#270400
#154500
#193500
Peutz-Jeghers syndrome
Von Hippel-Lindau Syndrome
Wilms tumor, WT1-related
Long QT syndrome
Long QT syndrome
Long QT syndrome
Familial lipodystrophy
Incontinentia Pigmenti
Restrictive dermopathy
Restrictive dermopathy
Alagille syndrome
Angelman syndrome
Antley-Bixler syndrome
ARC syndrome
ARX-related disorders
Beckwith-Wiedemann syndrome
CHARGE syndrome
Central hypoventilation syndrome
Currarino syndrome
Goltz-Gorlin syndrome
Holt-Oram syndrome
Marfan syndrome
Marfan syndrome II
Marfan syndrome II
Neurofibromatosis 1
Neurofibromatosis 2
Noonan syndrome
Noonan syndrome
LEOPARD syndrome
Norrie disease
Prader Willi syndrome
Rubinstein Taybi syndrome
Smith-Lemli-Opitz syndrome
Treacher Collins syndrome
Waardenburg syndrome
*602216
*608537
*607102
*607542
+152427
*600163
*150330
*300248
*606480
*150330
+601920
*182279
*124015
*608552
*300382
*600856
*103280
*604115
*608892
*603851
*142994
*601309
*601620
*134797
+190182
*190181
*613113
*607379
#163950
*176876
*300658
*182279
*600140
*602858
*606847
*606597
STK11
VHL
WT1
KCNQ1
KCNH2
SCN5A
LMNA
NEMO (IKBKG)
ZMPSTE24
LMNA
JAG1
UBE3A
POR
VPS33B
ARX
H9
LIT1
IGF2
CHD7
PHOX2B
HLXB9
PTCH
TBX5
FBN1
TGFBR2
TGFBR1
NF1
NF2
SOS1
PTPN11
NDP
SNRPN
CREBBP
DHCR7
TCOF1
PAX3
19p3.3
3p26-p25
11p13
11p15.5
12p11.1
3p21
1q21.2
Xq28
1p34
1q21.2
20p12
15q12
7q11.2
15q26.1
Xp22.13
11p15.5
8q12.1
4p12
7q36
9q22.3
12q24.1
15q21.1
3p22
9q22
17q11.2
22q12.2
2p22-p21
12q24.1
Xp11.4
15q12
16p13.3
11q12-q13
5q32-q33.1
2q35Genetic testing in clinical pediatric practice
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Table 3. Single Gene Disorders and Responsible Genes Where DNA-Based Genetic Testing Is Offered by the Medical Genetics Clinic
& Laboratory, Asan Medical Center Children’s Hospital (Continue)
Category OMIM Disease OMIM Gene Location
Endocrine
disease
Gastrointestinal
disease
Hematologic
disease
Immune
disease
#202110
#176410
#264600
#202200
#607398
#612965
#300068
#415000
#262600
+201910
#300200
#275200
#218700
#201710
#145980
#146110
+308700
#125850
#609734
+131100
#606176
#103580
#603233
#607200
#274500
#188570
#601410
#304800
#613217
#167800
#601847
#603553
#612304
+275350
#300755
#306400
#304790
#300400
#301000
17 hydroxylase deficiency
46, XY, DSD
5 alpha reductase deficiency
ACTH Resistance
ACTH Resistance
Adrenal failure
Adrenocortical dysplasia
Androgen insensitivity syndrome
Azoospermia
Combined pituitary hormone deficiency
Congenital adrenal hyperplasia
Congenital adrenal hypoplasia
Congenital Hypothyroidism
Congenital Hypothyroidism
Congenital lipoid adrenal hyperplasia
Hypocalciuric hypercalcemia
Hypogonadotropic hypogonadism
Kallmann syndrome 1
MODY1
Monogenic obesity
Multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 2A,B
PHHI, Neonatal DM
PHHI, Neonatal DM
PHHI, Neonatal DM
PHHI, Neonatal DM
Pseudohypoparathyroidism 1a
Pseudohypoparathyroidism 1b
SRY sequencing
Thyroid dyshormonogenesis
Thyroid dyshormonogenesis
Thyroid hormone resistance
Transient neonatal diabetes mellitus
X-linked nephrogenic DI
Congenital tufting enteropathy
Hereditary or familial pancreatitis
PFIC II
Familial hemophagocytic lymphohistiocytosis
Protein C deficiency
Transcobalamin II deficiency
Bruton's agammaglobulinemia
Chronic granulomatous disease
IPEX syndrome
Severe Combined Immunodeficiency, X-linked
Wiskott Aldrich syndrome
*609300
+152790
*607306
*607397
*609196
+184757
*609377
*313700
*601538
*173110
*601802
*600577
*602146
*313430
+201910
*300473
+603372
*167415
*600617
+601199
*138850
+308700
*600281
*176830
+131100
+164761
*600937
*138130
*138079
*600509
+139320
*480000
*606759
*606765
*190160
*606546
*300538
*185535
+276000
*167790
*601405
*603201
*170280
*612283
+275350
*300300
*300481
*300292
*308380
*300392
CYP17A1
LHCGR
SRD5A2
MC2R
MRAP
NR5A1(SF1)
ACD
AR
AZF
PROP1
POU1F1
HESX1
LHX3
LHX4
SOX3
CYP21A2
NR0B1
TSHR
PAX8
STAR
CASR
GNRHR
KAL1
HNF4A
POMC
MEN1
RET
KCNJ11
GLUD1 (GDH)
GCK
SUR1
GNAS
SRY
DUOX2
TPO
THRB
HYMA
AVPR2
EPCMA
PRSS1
SPINK1
CTRC
ABCB11
PRF1 (MUNC13-4)
PROC
TCN2
BTK
CYBB
FOXP3
IL2RG
WAS(IMD2)
10q24.3
2p21
2p23
18p11.2
21q22.1
9q33
16q22.1
Xq11-q12
Yq11.2
5q
3p11
3p21.2-p21.1
9q34.3
1q25
Xq26.3
6p21.3
Xp21.3-p21.2
14q31
2q12-q14
8p11.2
3q13.3-q21
4q21.2
Xp22.3
20q12-q13.1
2p23.3
11q13
10q11.2
11p15.1
10q23.3
7p15-p13
11p15.1
20q13.2
Yp11.3
15q15.3
2p25
3p24.3
6q24
Xq28
2p21
7q35
5q32
1p36.21
2q24
10q22
2q13-q14
22q11.2-qter
Xq21.3-q22
Xp21.1
Xp11.23-q13.3
Xq13
Xp11.23-p11.22HW Yoo
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Table 3. Single Gene Disorders and Responsible Genes Where DNA-Based Genetic Testing Is Offered by the Medical Genetics Clinic
& Laboratory, Asan Medical Center Children’s Hospital (Continue)
Category OMIM Disease OMIM Gene Location
Metabolic
disease
#250950
#210200
#143890
#300100
+107400
#207800
#207900
#237300
#212140
#255110
#219700
#605814
#215700
#220100
#177000
#301500
#162000
#227810
#230400
#230200
#230350
#256540
#230800
#231670
#231680
#232500
+232200
#232220
#232400
#234500
#229600
#238970
#236250
+236200
+309900
#607014
#259900
#239500
#307800
#602390
#245200
#609016
#300322
#309000
#222700
#248600
3-Methlyglutaconic aciduria 1
3-Methylcronylglycinuria
AD familial hypercholesterolemia
Adrenoleukodystrophy
Alpha-1 Antitrypsin deficiency
Arginase deficiency
Arginino-succinyl Lyase deficiency
Carbamoylphosphate synthetase I deficiency
Carnitine deficiency
Carnitine palmitoyltransferase II deficiency
CFTR-related disorders
Citrin deficiency
Citrullinemia
Cystinuria
Erythropoietic protoporphyria
Fabry disease
Familial hyperuricemia
Fanconi Bickel syndrome
Galactosemia
Galactosemia type 2
Galactosemia type 3
Galactosialidosis
Gaucher disease
Glutaricacidemia type 1
Glutaricacidemia type 2
Glycogen storage disease type IV
Glycogen storage disease type Ia
Glycogen storage disease type Ib
Glycogen storage disease type III
Hartnup disease
Hereditary fructose intolerance
HFE-associated hereditary hemochromatosis
HHH syndrome
Homocystinuria
Homocystinuria
Hunter syndrome
Hurler syndrome
Hyperoxaluria type 1
Hyperprolinemia 1
Hypophosphatemic Rickets,
Juvenile hemochromatosis
Krabbe disease
LCHAD deficiency
Lesch-Nyhan syndrome
LOWE syndrome
Lysiuric protein intolerance
Maple Syrup Urine disease
*600529
*609010
*609014
*606945
*300371
+107400
*608313
*608310
*608307
*603377
*600650
*602421
*603859
*603470
*104614
*612386
*300644
*191845
*138160
*606999
*604313
*606953
*613111
*606463
*608801
*608053
*130410
*231675
*607839
+232200
*602671
*610860
*608893
*612724
+235200
*603861
*607093
+236200
+309900
*252800
*604285
*606810
*300550
*608374
*606464
*606890
*600890
*143450
*308000
*300535
*603593
*238331
*248610
*608348
*248611
AUH
MCCA
MCCB
LDLR
ABCD1
SERPINA1
ARG1
ASL
CPS1
SLC22A5
CPT2
CFTR
SLC25A13
ASS
SLC3A1
FECH
GLA
UMOD
SLC2A2
GALT
GALK
GALE
PPGB
GBA
GCDH
ETFA
ETFB
ETFDH
GBE1
G6PC
SLC37A4
AGL
SLC6A19
ALDOB
HFE
ORNT1
MTHFR
CBS
IDS
IDUA
AGXT
PRODH
PHEX
HJV
HAMP
GALC
HADHA
HADHB
HPRT1
OCRL
SLC7A7
DLD
DBT
BCKDHA
BCKDHB
Chr.9
3q25-q27
5q12-q13
19p13.2
Xq28
14q32.1
6q23
7cen-q11.2
2q35
5q31.1
1p32
7q31.2
7q21.3
9q34.1
2p16.3
18q21.3
Xq22
16p12.3
3q26.1-q26.3
9p13
17q24
1p36-p35
20q13.1
1q21
19p13.2
15q23-q25
19q13.3
4q32-qter
3p12
17q21
11q23
1p21
5p15.33
9q22.3
6p21.3
13q14
1p36.3
21q22.3
Xq28
4p16.3
2q36-q37
22q11.2
Xp22.2-p22.1
1q21
19q13
14q31
2p23
2p23
Xq26-q27.2
Xq26.1
14q11.2
7q31-q32
1p31
6q14
19q13.1-q13.2Genetic testing in clinical pediatric practice
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Table 3. Single Gene Disorders and Responsible Genes Where DNA-Based Genetic Testing Is Offered by the Medical Genetics Clinic
& Laboratory, Asan Medical Center Children’s Hospital (Continue)
Category OMIM Disease OMIM Gene Location
Mitochondrial
disease
Muscular
disease
Neurologic
disease
Ophthalmologic
disease
Otologic
disease
#256000
#256000
#535000
#540000
#545000
#580000
#310200
#300376
#310300
#160900
#602668
#310400
#253300
#125310
#116860
#118220
#302800
#128230
#125370
#128100
#300624
#229300
#143100
#312750
#254800
#121200
#234200
#600116
#312080
#182600
#182601
#600363
#313200
#164400
#603516
#604326
#607136
#183090
#109150
#183086
#164500
#608768
#191100
#106210
#607541
#133780
+312700
#153700
#220290
Leigh syndrome
Leigh syndrome
LHON
MELAS
MERRF
Nonsyndromic hearing loss, mitochondrial
Duchenn muscular dystrophy
Becker muscular dystrophy
Emery-Dreifuss Muscular dystrophy
Myotonic dystrophy type 1
Myotonic dystrophy type 2
Myotubular myopathy type 1
Spinal muscular atrophy
CADASIL
Cerebral Cavernous Malformation
Charcot-Marie-Tooth neuropathy type 1A
Charcot-Marie-Tooth neuropathy type X
Dopa-responsive dystonia
DRPLA
Early-onset torsion dystonia
FMR1-related disorders
Friedreich Ataxia
Huntington disease
MECP2-related disorders
Myoclonic epilepsy, Unverricht and Lundborg
Neonatal epilepsy 1
Pantothenate kinase-associated neurodegeneration
Parkinson disease
Pelizaeus-Merzbacher disease
Spastic paraplegia type 3A
Spastic paraplegia type 4
Spastic paraplegia type 6
Spinal and bulbar muscular atrophy
Spinocerebellar ataxia type 1
Spinocerebellar ataxia type 10
Spinocerebellar ataxia type 12
Spinocerebellar ataxia type 17
Spinocerebellar ataxia type 2
Spinocerebellar ataxia type 3
Spinocerebellar ataxia type 6
Spinocerebellar ataxia type 7
Spinocerebellar ataxia type 8
Tuberous sclerosis complex
Aniridia
Corneal dystrophy, avellinotype
Exudative Vitreoretinopathy type 1 (EVR1)
Retinoschisis, X-linked
Vitelliform macular dystrophy
Nonsyndromic deafness, Cx26
+516060
*185620
*516003
*590050
*590060
*561000
*300377
*300384
*605377
*116955
*300415
*600354
*600276
*604214
*607929
*609118
*601097
*304040
*600225
*607462
*605204
*309550
*606829
*613004
*300005
*601145
*602235
*606157
*602544
*300401
*606439
*604277
*608145
*313700
*601556
*611150
*604325
*600075
*601517
*607047
*601011
*607640
*603680
*605284
*191092
*607108
*601692
*604579
+312700
*607854
*121011
MTATP6
SURF1
MTND4
MTTL1; MTND5
MTTK
MTRNA1; MTTS1
DMD
EMD
DMPK
CNBP
MTM1
SMN1
NOTCH3
CCM1
CCM2
CCM3
PMP22
GJB1
GCH1
DRPLA
TOR1A
FMR1
FRDA
HD
MECP2
CSTB
KCNQ2
PANK2
PARK2
PLP1
SPG3A
SPG4
SPG6
AR
ATXN1
SCA10
SCA12
SCA17
ATXN2
MJD
CACNA1A
SCA7
SCA8
TSC1
TSC2
PAX6
TGFB1
FZD4
XLRS1
VMD2
GJB2
9q34
Xp21.2
Xq28
19q13.2-q13.3
3q13.3-q24
Xq28
15q12.2-q13.3
19p13.2-p13.1
7q11.2-q21
7p13
3q26.1
17p11.2
Xq13.1
14q22.1-q22.2.
12p13.31
9q34.
Xq27.3.
9q13.
4p16.3
Xq28
21q22.3
20q13.3
20p13-p12.3
6q25.2-q27
Xq22
14q11-q21
2p22-p21
15q11.1
Xq11-12.
6p23.
22q13
5q31-q33
6q27
12q24.1.
14q32.1.
19p13.
3p21.1-p12.
13q21
9q34
16p13.3
11p13
5q31
11q14-q21
Xp22.2-p22.1
11q13
13q11-q12HW Yoo
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in Table 4, Prader-Willi/Angelman syndromes (PWS/AS)
are prototypes of such epigenetic disorders. To date, at
least six disorders are known to be caused by epigenetic
changes: PWS/AS, Beckwith-Wiedemann syndrome (BWS),
Silver-Russell syndrome (SRS), Albright hereditary osteo-
dystrophy (AHO)/pseudohypoparathyroidism (PHP), and
transient neonatal diabetes mellitus
10) (Table 4).
5. Pharmacogenetic DNA testing
Pharmacogenetic DNA testing is an example of a genetic
test that offers the potential of predicting the response to
a particular drug by an individual patient. This enables
precise tailoring of drug dosages for maximum efficacy,
reduction of adverse reactions and identification of drugs
that should be avoided altogether. In pediatric practice,
pharmacogenetic tests for sensitivity to mercaptopurine, a
drug used for acute childhood leukemia, is one example. In
this case, the activity of the enzyme thiopurinemethyltrans-
ferase (TPMT) varies among individuals due to a variant of
the TPMT gene. Pharmacogenetic testing will be increa-
singly used in clinical practice in the near future. However,
many different genes involved in the pharmacokinetics and
pharmacodynamics of drug metabolism should be exten-
sively analyzed simultaneously to enhance the sensitivity
and specificity of prediction
14-17). The following currently
used pharmacogenetic tests have demonstrated clinical
utility and validity:
1) Warfarin genotyping: cytochrome P450 enzyme 2C9
(CYP2C9) and vitamin K oxide receptor complex-1
(VKORC1)
2) Slow/rapid acetylator genotyping: N-acetyl trans-
ferase 2 (NAT2) gene
3) Thiopurine drug (6-MP, 6-thioguanine, azathioprine)
metabolism genotyping: thiopurine methyltransferase
(TPMT) gene
6. SNP-based disease-susceptibility genetic testing
The use of SNP-based disease-susceptibility tests tends
to be clinically justified because the disease categories
covered include more common disorders that represent a
greater socio-economic burden to the health care system.
However, the clinical and analytical validity of such tests
Table 4. Genetic Disorders Associated with Imprinting Defects
Genetic Disorder OMIM# Chromosome Gene(s) Imprinted
Angelman syndrome
Prader-Willi syndrome
Beckwith-Wiedemann syndrome
Silver-Russell syndrome
AHO/PHP 1a, pPHP
105830
176270
130650
180860
103580
15q11-13
15q11-13
11p15.5
11p15.5
7p11.2-p13
20q13.3
UBE3A
SNRPN
Others (MKRN3, NDN)
H19
IGFII
CDKN1C
H19
GRB10
GNAS1
Pat
Mat
Mat
Pat
Mat
Pat
Pat
Mat
Pat
Table 3. Single Gene Disorders and Responsible Genes Where DNA-Based Genetic Testing Is Offered by the Medical Genetics Clinic
& Laboratory, Asan Medical Center Children’s Hospital (Continue)
Category OMIM Disease OMIM Gene Location
Renal
disease
Skeletal
disease
#300009
#256100
#220150
#100800
#114290
#146000
#166200
#215100
#183900
#107480
Dent's syndrome
Nephronophthisis 1
Renal hypouricemia
Achondroplasia
Campomelic dysplasia, sex-reversal
FGFR2-related craniosynostosis
FGFR3-related craniosynostosis
Hypochondroplasia
Osteogenesis Imperfecta
Rhizomelic chondrodysplasia punctata type 1
Spondyloepiphyseal dysplasia
Townes Brocks syndrome
*300008
*607100
*607096
*134934
*608160
*176943
*134934
*134934
+120150
*120160
+601757
+120140
*602218
CLCN5
NPHP1
SLC22A12
FGFR3
SOX9
FGFR2
FGFR3
FGFR3
COL1A1
COL1A2
PEX7
COL2A1
SALL1
Xp11.22
2q13
11q13
4p16.3.
17q24.3-q25.1
10q26.
4p16.3.
4p16.3.
17q21.31-q22
7q22.1
6q22-q24
12q13.11-q13.2
16q12.1Genetic testing in clinical pediatric practice
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do not reach a level that warrants their recognition as bona
fide clinical tests. Obtaining clinically significant genetic
data in certain ethnic groups using SNP-based disease-
susceptibility tests requires a collective analysis of nume-
rous genes and SNPs in both normal and patient populations.
As statistical genetics and new technologies continue to
rapidly develop, SNP-based disease-susceptibility genetic
tests can be expected to play a growing role in the mana-
gement of more common diseases in a clinical practice set-
ting, although this increasing use will also raise tremendous
ethical, legal, and social issues. The following currently
used tests have demonstrated a degree of clinical utility
and validity in specific populations
18-20):
1) Thrombophilia panel: factor V Leiden, prothrombin
(factor II) and MTHFR (methylenetetrahydrofolate reduc-
tase) genes
2) Coronary heart disease: lipoprotein (Lp(a), apoE),
coagulation factor, and MTHFR genes
3) Hypertension: angiotensin-converting enzyme (ACE)
gene
4) Insulin-dependent diabetes mellitus: HLA genes
5) Cancer disease: BRACA1, BRACA2, Rb, adenomatosis
polyposis coli (APC), and N-myc, BCR-ABL genes
6) Hemochromatosis: HFE gene (population screening
in Caucasians)
7) Alzheimer s disease: Apo E gene ’
8) Neural tube defect: MTHFR gene
7. Chromosome microdeletion syndrome (Table 5)
Molecular cytogenetic testing has progressed since the
late 1980s with the advent of new molecular biology tech-
niques. One such technique is FISH, in which purified
single-stranded DNA sequences labeled with a fluorescent
dye are hybridized to target complementary single-stranded
chromosomal DNA sequences in the interphase or metap-
hase state. The resolution of FISH is limited by the size of
the probes required to generate detectable fluorescence.
FISH testing can be undertaken to diagnose microdeletion/
duplication syndrome in cases where there is a high clinical
suspicion of such a condition. Subtelomeric FISH is usually
recommended for assessing patients with developmental
delay or failure to thrive. Recently, arrayed CGH using
dense SNP chips have allowed the detection of minute
chromosomal structural aberrations at extremely high re-
solution and led to the discovery of new dysmorphic syn-
dromes caused by chromosome microdeletion/duplication.
However, copy number variations can exist that have un-
certain clinical significance, and therefore, the results of
such analyses should be interpreted with caution. Table 5
summarizes microdeletion syndromes that are diagnosed
by FISH
10, 21).
8. Direct-to-consumer (DTC) genetic testing
The term direct-to-consumer genetic testing has been “ ”
used variously to refer to both the advertising and sale of
genetic tests. The best known and most controversial
example is Myriads advertising campaign in the United ’
States for its BRACAnalysis test, which predicts predispo-
sition to hereditary breast and ovarian cancers. DTC gene-
tic tests may be made available in one of two ways. In the
first, the availability of the test is advertised to the public,
but the test must be prescribed by a healthcare provider,
who also receives the test results. Alternatively, genetic
tests may be advertised and directly marketed to the con-
sumer, who can initiate the purchase of genetic tests/ser-
vices and receive the results without involvement of a
health care provider. The most common access to direct-
marketed tests is via the Internet. Numerous commercial
laboratories offer tests for trait and disease susceptibility
of unproven clinical and analytical validity. In Korea, the
government has implemented legislation to prohibit DTC
genetic tests by law. However, there should be a serious
government policy discussion of the clinical validity of DTC
genetic tests as well as their potential for benefit or harm.
Equally important are considerations of who has the right
to make the decision to purchase DTC genetic tests, who
regulates or supervises these tests, and how they are ad-
ministered. In fact, the DTC genetic testing market is ra-
pidly expanding and is becoming a business model of the
Table 5. Microdeletion Syndromes Diagnosed by FISH
Syndromes Deletion of chromosome locus
1p deletion
Soto
Williams
WAGR
Jacobsen
Prader-Willi
Angelman
Rubinstein-Taybi
Smith-Magenis
Miller-Dieker
Alagille
DiGeorge/Velocardiofacial
1p36
5q35
7q11.23
11p13
11q24.1-qter
15q11-q13 (pat)
15q11-q13 (mat)
16p13.3
17p11.2
17p13.3
20p12
22q11.2HW Yoo
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future. Many DTC genetic testing companies are flourishing,
offering susceptibility testing for common diseases and
ancestry testing (23 and Me); for cancers, diabetes and
heart disease (deCODE); for risk analysis for more than 20
common diseases, including prostate cancer and diabetes
(Navigenics); and for diverse pharmacogenetic testing
(Genelex). The American College of Medical Genetics is-
sued the following statement on DTC genetic testing: A “
knowledgeable professional should be involved in the pro-
cess of ordering and interpreting a genetic test. The con-
sumer should be fully informed regarding what the test can
and cannot say about his or her health. The scientific evi-
dence on which a test is based should be clearly stated.
The clinical testing laboratory must be accredited by ap-
plicable accrediting agencies. Privacy concerns must be
addressed”
21-23).
Ethical, legal, and social implications of genetic testing
Genetic testing raises complex ethical, legal, and social
issues. The health care providers involved with genetic
testing must take extreme care to respect the human rights
of tested individuals and their relatives. Maximal efforts
should be made to protect the genetic privacy of those
tested against possible discrimination in job opportunities,
education, or insurance based on genetic information. In-
formed consent should be obtained via pretest genetic
counseling that covers the following elements: purpose,
methods, implications, diagnostic limitations (accuracy),
alternatives to genetic testing, cost of the test, accurate
information on any harm or medical risks associated with
the test, and the necessity of post-test counseling to ex-
plain the clinical significance of the results. A decision on
whether to undergo genetic testing should be made freely
and autonomously by the examinee. The physicians must
explain the individual s right not to be tested, to withdraw ’
at any time, and to refuse disclosure of data after testing.
The examinee should be fully informed that test results
might not be used to improve treatment modalities. In pe-
diatric cases, where the patient is incapable of autonomous
decision-making, the consent of a surrogate representative
must be sought. Pediatric genetic testing for adult-onset
genetic diseases where no effective preventive or thera-
peutic options exist should be avoided. The right of exa-
minees to know or not to know the results should be equally
respected. Genetic counseling must be non-directive, and
designed to maximize patients benefits and minimize harm. ’
Genetic testing for the characterization of traits should not
be recommended for reasons of uncertain scientific validity
as well as ethical concerns. Discretion should be applied in
recommending SNP-based DNA testing for predisposition
to common diseases
21, 24-28).
Conclusion
Genetic testing has rapidly progressed during recent
decades and has already become incorporated into daily
routine clinical practice. Pediatricians increasingly face is-
sues involving genetic testing. Therefore, it is very im-
portant that physicians have a basic understanding of the
range of possible tests, indications for their utility, and
pitfalls in their interpretation. In the near future, the appli-
cation of genetic testing to common disorders is expected
to expand, and such tests will likely be extended to include
individual pharmacogenetic assessments. Awareness of the
pros and cons of genetic testing by the public and health
care professionals should be enhanced by continuing edu-
cation.
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